Efficacy of Bismuth‐Based Triple Therapy in Children With Abdominal Pain and Helicobacter pylori Gastritis

Abstract

Background:To evaluate the effect of a therapeutic regimen of 7 days versus 14 days on the clinical manifestations of Helicobacter pylori gastritis in children.Methods:Ninety children (age 2–19 years) who had abdominal pain and/or recurrent vomiting were determined to have H. pylori gastritis by endoscopy, histology, and a Giemsa stain positive for H. pylori. The patients were randomized to receive amoxicillin, metronidazole, and bismuth subcitrate for 7 days (group A; 45 children) or 14 days (group B; 45 children) and were observed clinically for 19 ± 11.5 months. Resolution of all abdominal and gastrointestinal symptoms was considered a good response.Results:A good response was obtained in 36 (80%) children from group A, and in 37 (82%) from group B. A recurrence of symptoms occurred in four (11%) of the responders from group A, and in six (15.2%) from group B.Conclusions:A 7‐day course of bismuth‐based triple therapy for H. pylori gastritis in children appears to be clinically as effective as a 14‐day regimen. The feasibility of a shorter therapeutic regimen may enhance patient compliance and provide a better chance of clinical benefit.